Clinical Cardiology Alert – February 1, 2003
February 1, 2003
View Issues
-
The Metabolic Syndrome and Cardiovascular Mortality
The metabolic syndrome (tms), also known as the deadly quartet, Reavens syndrome, the insulin resistance syndrome, etc, has attracted considerable attention over the past few years, as it has been suspected that individuals with TMS are at increased risk for vascular disease, as well as the development of type 2 diabetes. -
IIb/IIIa Inhibition for PCI of Bypass Grafts
The long-term success of revascularization by coronary artery bypass graft (CABG) surgery is not infrequently limited by degeneration, and ultimately failure, of venous conduits. -
Rate Control vs Rhythm Control In Atrial Fibrillation
Synopsis: There was no overall benefit to a rhythm control strategy. Therefore, rate control should be considered a primary therapeutic option, and rhythm control, if elected, may be abandoned early if not fully satisfactory. -
Doppler Estimation of Pulmonary Diastolic Pressure
Doppler echocardiographic techniques for estimating pulmonary artery (PA) systolic pressure (SP) and diastolic pressure (DP) using tricuspid (TR) and pulmonic valve (PV) regurgitation (PR), jet velocity and estimation of right atrial pressure (RAP) usually by inspection of the size and dynamics of the inferior vena cava (IVC) have been well described. -
The Dual Chamber and VVI Implantable Defibrillator (DAVID) Trial
Synopsis: DDDR pacing using a right ventricular lead in patients without an indication for antibradycardia pacing is detrimental. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch: FDA Issues ‘Black Box’ Warning Based on WHI Study
The FDA has mandated a Black Box warning for all estrogen and estrogen/progestin products for use by postmenopausal women. The new warnings are based on analysis of data from the Womens Health Initiative (WHI) study that was published July 2002.